Tag Archives: EW

Best Heal Care Stocks To Own For 2019

Brokerages forecast that Acadia Healthcare Company Inc (NASDAQ:ACHC) will announce $0.70 earnings per share for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Acadia Healthcare’s earnings. The highest EPS estimate is $0.77 and the lowest is $0.68. Acadia Healthcare reported earnings per share of $0.66 in the same quarter last year, which would suggest a positive year over year growth rate of 6.1%. The company is scheduled to announce its next earnings results on Thursday, July 26th.

According to Zacks, analysts expect that Acadia Healthcare will report full year earnings of $2.58 per share for the current year, with EPS estimates ranging from $2.44 to $2.62. For the next year, analysts forecast that the company will report earnings of $2.82 per share, with EPS estimates ranging from $2.61 to $3.00. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Acadia Healthcare.

Best Heal Care Stocks To Own For 2019: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By ]

    In the Lightning Round, Cramer was bullish on Align Technology (ALGN) , Regions Financial (RF) , Edwards Lifesciences (EW) , Qualys (QLYS) and HEICO (HEI) .

  • [By ]

    Edwards Lifesciences (EW) : “They have the best devices. That stock is a buy.”

    Align Technology (ALGN) : “The stock is breaking down. Let’s wait a few days then pull the trigger.”

  • [By Lisa Levin]

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Edwards Lifesciences Corp (NYSE: EW) reported better-than-expected results for its first quarter, but issued weak earnings guidance for the second quarter. Edwards Lifesciences shares tumbled 7.80 percent to $124.17 in the after-hour

Best Heal Care Stocks To Own For 2019: Super Micro Computer, Inc.(SMCI)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Friday, the information technology shares rose 1.59 percent. Meanwhile, top gainers in the sector included Pandora Media, Inc. (NYSE: P), up 23 percent, and Super Micro Computer, Inc. (NASDAQ: SMCI) up 17 percent.

  • [By Stephan Byrd]

    BidaskClub upgraded shares of Super Micro Computer (NASDAQ:SMCI) from a sell rating to a hold rating in a research note published on Friday.

    A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Super Micro Computer from a strong-buy rating to a hold rating in a research note on Thursday, April 5th. Maxim Group increased their price objective on shares of Super Micro Computer from $45.00 to $50.00 and gave the company a buy rating in a research note on Wednesday, January 31st. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $28.14.

  • [By Lisa Levin]

    Friday afternoon, the information technology shares rose 1.9 percent. Meanwhile, top gainers in the sector included Pandora Media, Inc. (NYSE: P), up 23 percent, and Super Micro Computer, Inc. (NASDAQ: SMCI) up 16 percent.

  • [By Lisa Levin] Gainers
    Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares jumped 29.86 percent to close at $2.87 on Friday.
    Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares gained 28.87 percent to close at $8.75 after reporting upbeat Q1 earnings.
    Mexco Energy Corporation (NYSE: MXC) gained 27.02 percent to close at $5.4744.
    Carbon Black, Inc. (NASDAQ: CBLK) climbed 26 percent to close at $23.94. Carbon Black priced its IPO at $19 per share.
    Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) rose 25.64 percent to close at $42.44 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban.
    Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.19 percent to close at $8.50 after reporting Q2 results.
    California Resources Corporation (NYSE: CRC) shares gained 22.45 percent to close at $31.58 following upbeat Q1 earnings.
    Atomera Incorporated (NASDAQ: ATOM) gained 22.31 percent to close at $6.25 after reporting Q1 results.
    Medifast, Inc. (NYSE: MED) shares jumped 22.27 percent to close at $121.46 after the company reported strong Q1 results and raised its FY18 guidance.
    Jerash Holdings (US), Inc. (NASDAQ: JRSH) gained 20.86 percent to close at $8.46.
    Pandora Media, Inc. (NYSE: P) rose 19.83 percent to close at $6.89 after reporting strong quarterly results.
    Shake Shack Inc (NYSE: SHAK) rose 18.01 percent to close at $55.95 on Friday after the company reported upbeat results for its first quarter and raised its FY18 guidance.
    Super Micro Computer, Inc. (NASDAQ: SMCI) rose 17.73 percent to close at $21.25 after reporting strong preliminary results for the third quarter.
    Schmitt Industries, Inc. (NASDAQ: SMIT) rose 17.41 percent to close at $2.36.
    Titan International, Inc. (NYSE: TWI) shares gained 16.78 percent to close at $12.25 following Q1 earnings.
    Integer Holdings Corporation (NYSE: ITGR) shares rose 14.23 percent to close at $63.40 following Q1 result
  • [By Lisa Levin] Gainers
    Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares rose 35.8 percent to $3.00.
    Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares surged 32 percent to $8.94 after reporting upbeat Q1 earnings.
    Carbon Black, Inc. (NASDAQ: CBLK) gained 29.6 percent to $24.62. Carbon Black priced its IPO at $19 per share.
    California Resources Corporation (NYSE: CRC) shares rose 26.8 percent to $32.70 following upbeat Q1 earnings.
    Pandora Media, Inc. (NYSE: P) gained 25 percent to $7.185 after reporting strong quarterly results.
    Medifast, Inc. (NYSE: MED) shares climbed 23.7 percent to $122.87 after the company reported strong Q1 results and raised its FY18 guidance.
    Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.2 percent to $8.4999 after reporting Q2 results.
    Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) gained 22.2 percent to $41.27 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban.
    Shake Shack Inc (NYSE: SHAK) rose 22.2 percent to $57.955 after the company reported upbeat results for its first quarter and raised its FY18 guidance.
    Atomera Incorporated (NASDAQ: ATOM) jumped 19.7 percent to $6.12 after reporting Q1 results.
    Super Micro Computer, Inc. (NASDAQ: SMCI) rose 16.4 percent to $21.00 after reporting strong preliminary results for the third quarter.
    Titan International, Inc. (NYSE: TWI) shares rose 16.4 percent to $12.21 following Q1 earnings.
    Integer Holdings Corporation (NYSE: ITGR) shares gained 14.9 percent to $63.75 following Q1 results.
    Control4 Corporation (NASDAQ: CTRL) shares climbed 14.5 percent to $23.98 folloiwng strong Q1 results.
    B&G Foods, Inc. (NYSE: BGS) climbed 12.6 percent to $25.40 after reporting Q1 earnings.
    HMS Holdings Corp (NASDAQ: HMSY) shares gained 10 percent to $19.59 after reporting upbeat quarterly earnings.
    Viavi Solutions Inc. (NASDAQ: VIAV) rose 7 percent to $10.09 following Q3 r

Best Heal Care Stocks To Own For 2019: KBR, Inc.(KBR)

Advisors’ Opinion:

  • [By ]

    KBR (NYSE: KBR)
    Though an under-the-radar name, KBR was the construction arm of oilfield services giant Halliburton (NYSE: HAL) before being spun off. With a consolidated market cap of $2.6 billion, KBR describes itself, per its website, as a “global provider of differentiated professional services and technologies within the Government Services and Hydrocarbon sectors.”

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on KBR (KBR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Heal Care Stocks To Own For 2019: Natural Health Trends Corp.(NHTC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday.
    Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday.
    Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday.
    Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday.
    Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral.
    Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018.
    Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading.
    Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading

Best Heal Care Stocks To Own For 2019: United Technologies Corporation(UTX)

Advisors’ Opinion:

  • [By Paul Ausick]

    United Technologies Corp. (NYSE: UTX) traded up 1.92% at $127.28 in a 52-week range of $109.10 to $139.24. Volume was about equal to the daily average of around 3.9 million shares.

  • [By Paul Ausick]

    The DJIA stock posting the largest daily percentage gain ahead of the close Thursday was United Technologies Corp. (NYSE: UTX) which traded up 3.33% at $133.56. The stock’s 52-week range is $107.05 to $139.24. Volume was about 50% above the daily average of around 4.3 million shares. The company’s CEO said that company is considering breaking itself into three pieces.

  • [By Paul Ausick]

    United Technologies Corp. (NYSE: UTX) traded up 1.23% at $134.45. The stock’s 52-week range is $106.85 to $135.79. Volume was about 15% above the daily average of around 3 million shares. The company had no specific news today, but Monday’s Goldman Sachs ratings upgrade to Buy with a $50 bump in the target price to $173 is still paying off for UTC.

  • [By ]

    Case in point: United Technologies (UTX) , which posted a spectacular quarter because it’s products are in demand and the company can easily raise prices to offset rising commodity costs.

Best Heal Care Stocks To Own For 2019: Jupai Holdings Limited(JP)

Advisors’ Opinion:

  • [By Lisa Levin]

    Jupai Holdings Limited (NYSE: JP) shares shot up 16 percent to $26.48 after reporting Q1 results.

    Shares of American Woodmark Corporation (NASDAQ: AMWD) got a boost, shooting up 13 percent to $100.05 after the company reported upbeat Q4 results.

  • [By Lisa Levin] Gainers
    Axovant Sciences Ltd. (NASDAQ: AXON) shares rose 23.7 percent to $1.49. Axovant announced strengthening of management team and completion of organization restructuring which "enhanced capabilities in research and business development" and reduced internal headcount by 43 percent.
    Mammoth Energy Services, Inc. (NASDAQ: TUSK) shares jumped 19.8 percent to $37.3148. Mammoth Energy’s subsidiary Cobra signed a new $900 million contract to finish the restoration of critical electrical services and support the initial phase of reconstruction of the electrical utility system in Puerto Rico.
    Acorn International, Inc. (NYSE: ATV) shares gained 19 percent to $34.0201. Acorn shares rose Friday after the company declared a special one-time cash dividend of $14.97 per ADS.
    DHI Group, Inc. (NYSE: DHX) shares surged 19 percent to $2.20.
    My Size, Inc. (NASDAQ: MYSZ) climbed 16.8 percent to $1.18 after the company received a Notice of Allowance from the USPTO for measurement technology patent.
    Global Eagle Entertainment Inc. (NASDAQ: ENT) gained 16.6 percent to $2.32.
    Leju Holdings Limited (NYSE: LEJU) gained 16.5 percent to $1.34 following Q1 beat.
    Evolus, Inc. (NASDAQ: EOLS) shares surged 16.5 percent to $26.1499. Evolus named Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development.
    Jupai Holdings Limited (NYSE: JP) shares gained 15 percent to $26.29 after reporting Q1 results.
    Momo Inc. (NASDAQ: MOMO) shares gained 15 percent to $44.7702 after the company reported better-than-expected results for its first quarter and issued strong sales forecast for the second quarter.
    Windstream Holdings, Inc. (NASDAQ: WIN) rose 15 percent to $7.075.
    China Advanced Construction Materials Group, Inc. (NASDAQ: CADC) gained 14.4 percent to $2.746.
    American Woodmark Corporation (NASDAQ: AMWD) climbed 14.2 percent to $101.10 after the company reported upbeat Q4 results.
    Savara Inc. (NAS
  • [By Lisa Levin] Gainers
    TransEnterix, Inc. (NYSE: TRXC) rose 28.8 percent to $4.03 in pre-market trading after the company disclosed that it has received the FDA clearance for expanded indications for its Senhance Surgical System.
    Global Eagle Entertainment Inc. (NASDAQ: ENT) rose 15.6 percent to $2.30 in pre-market trading.
    Companhia Brasileira de Distribuição (NYSE: CBD) rose 13.2 percent to $24.20 in pre-market trading.
    ZTO Express (Cayman) Inc. (NYSE: ZTO) rose 12.2 percent to $21.65 in pre-market trading. Alibaba and Cainiao agreed to make strategic investment in ZTO Express of $1.38 billion.
    DHI Group, Inc. (NYSE: DHX) rose 10.8 percent to $2.05 in pre-market trading.
    Momo Inc. (NASDAQ: MOMO) shares rose 9.6 percent to $42.68 in pre-market trading after the company reported better-than-expected results for its first quarter and issued strong sales forecast for the second quarter.
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares rose 9.1 percent to $6.00 in pre-market trading.
    Universal Display Corporation (NASDAQ: OLED) rose 8.4 percent to $108.00 in pre-market trading.
    Jupai Holdings Limited (NYSE: JP) shares rose 7 percent to $24.50 in pre-market trading after reporting Q1 results.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) rose 5.9 percent to $10.61 in pre-market trading.
    Frontline Ltd. (NYSE: FRO) rose 5.9 percent to $5.04 in pre-market trading.
    Evogene Ltd. (NASDAQ: EVGN) rose 5.5 percent to $3.27 in pre-market trading after reporting Q1 results.
    Sears Holdings Corporation (NASDAQ: SHLD) rose 5.5 percent to $3.68 in pre-market trading after gaining 5.44 percent on Friday.
    Kitov Pharma Ltd (NASDAQ: KTOV) shares rose 5.4 percent to $2.16 in pre-market trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Lisa Levin]

    On Tuesday, the financial shares surged 0.71 percent. Meanwhile, top gainers in the sector included Guaranty Bancorp (NASDAQ: GBNK), up 5 percent, and Jupai Holdings Limited (NYSE: JP) up 5 percent.

Top 5 High Tech Stocks To Buy Right Now

Wells Fargo’s quest to clean up its act requires workers to shine a light on shady activity when they see it.

A top Wells Fargo (WFC) executive said on Tuesday that employees are increasingly using the bank’s confidential hotline to report bad behavior.

“Our volumes increased on our ethics line. We’re glad they did. People raised their hand,” said Theresa LaPlaca, who leads a conduct office that Wells Fargo created last year.

“That is success for me,” LaPlaca said at the ACFE Global Fraud Conference in Las Vegas.

Reassuring Wells Fargo workers to trust the bank’s ethics hotline is no easy task. Nearly half a dozen workers told CNNMoney in 2016 that they were fired by Wells Fargo after calling the hotline to try to stop the bank’s fake-account problem.

Last year, Wells Fargo was ordered to re-hire and pay $5.4 million to a whistleblower who was fired after calling the ethics hotline to report suspected fraud. Wells Fargo faces multiple lawsuits from employees who say they protested sales misconduct. The bank said in a filing that it also faces state law whistleblower actions filed with the Labor Department alleging retaliation.

Top 5 High Tech Stocks To Buy Right Now: BlackRock Strategic Municipal Trust Inc. (BSD)

Advisors’ Opinion:

  • [By Logan Wallace]

    BitSend (CURRENCY:BSD) traded 3.6% higher against the U.S. dollar during the one day period ending at 21:00 PM Eastern on June 2nd. One BitSend coin can currently be bought for approximately $0.53 or 0.00006976 BTC on popular cryptocurrency exchanges including Livecoin, Cryptopia, SouthXchange and LiteBit.eu. BitSend has a market cap of $10.33 million and approximately $22,076.00 worth of BitSend was traded on exchanges in the last 24 hours. In the last seven days, BitSend has traded up 2.3% against the U.S. dollar.

  • [By Ethan Ryder]

    BitSend (BSD) is a PoW/PoS coin that uses the X11 hashing algorithm. BitSend’s total supply is 19,754,725 coins. BitSend’s official Twitter account is @Bit_send. The official website for BitSend is www.bitsend.info.

  • [By Ethan Ryder]

    BitSend (CURRENCY:BSD) traded down 8.9% against the U.S. dollar during the 1 day period ending at 16:00 PM Eastern on June 20th. During the last week, BitSend has traded 5.1% higher against the U.S. dollar. BitSend has a market cap of $6.58 million and approximately $147,698.00 worth of BitSend was traded on exchanges in the last 24 hours. One BitSend coin can now be purchased for approximately $0.34 or 0.00004993 BTC on major exchanges including LiteBit.eu, Cryptopia, SouthXchange and Bittrex.

Top 5 High Tech Stocks To Buy Right Now: NVE Corporation(NVEC)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Kayne Anderson Rudnick Investment Management LLC increased its holdings in NVE Co. (NASDAQ:NVEC) by 1.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 741,605 shares of the semiconductor company’s stock after purchasing an additional 9,645 shares during the period. Kayne Anderson Rudnick Investment Management LLC owned approximately 15.32% of NVE worth $61,635,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    NVE Co. (NASDAQ:NVEC) shares hit a new 52-week high and low on Wednesday . The stock traded as low as $105.88 and last traded at $103.80, with a volume of 52 shares changing hands. The stock had previously closed at $104.57.

  • [By Motley Fool Transcribing]

    NVE (NASDAQ:NVEC) Q1 2019 Earnings Conference CallJul. 18, 2018 4:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 High Tech Stocks To Buy Right Now: Pacific Biosciences of California Inc.(PACB)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

  • [By Paul Ausick]

    Pacific Biosciences of California Inc. (NASDAQ: PACB) slipped about 5.6% to post a new 52-week low of $2.52 Tuesday after closing at $2.67 on Friday. Volume of about 910,000 was about 10% above the daily average. The company had no specific news.

  • [By Keith Speights]

    Shares of Pacific Biosciences of California Inc. (NASDAQ:PACB) dropped 9.7% as of 3 p.m. EDT Monday on worries of an escalating trade war between the U.S. and China. The Wall Street Journal reported earlierthat President Trump plans to prevent many Chinese companies from investing in U.S. technology companies and wants to limit U.S. technology exports to China.

  • [By Keith Speights]

    Gene sequencing is hot these days. All you have to do to confirm it is to look at the stock performance of two of the leading makers of gene-sequencing systems. Illumina (NASDAQ:ILMN) stock is up more than 30% so far in 2018. Pacific Biosciences of California (NASDAQ:PACB) stock has soared more than 50% year to date.

  • [By Cory Renauer]

    Shares of Pacific Biosciences of California(NASDAQ:PACB),a genetic-sequencing system manufacturer, rose 11% on Thursday and continued their climb into Friday’s session. Investors appear pleased with new productivity-boosting tools to be featured at this week’s meeting of the American Society for Microbiology.

  • [By Maxx Chatsko]

    Shares of Pacific Biosciences of California (NASDAQ:PACB) jumped over 40% last month after the company announced new multiplexing tools at the American Society of Microbiology (ASM) annual meeting. Multiplexing allows researchers to combine multiple samples and sequence them simultaneously, which provides results more quickly and at lower cost.

Top 5 High Tech Stocks To Buy Right Now: American Tower Corporation (REIT)(AMT)

Advisors’ Opinion:

  • [By Max Byerly]

    American Tower (NYSE:AMT) was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, MarketBeat Ratings reports. They presently have a $135.00 target price on the real estate investment trust’s stock. Guggenheim’s target price would indicate a potential downside of 5.04% from the company’s previous close.

  • [By Matthew Frankel]

    American Tower (NYSE:AMT), despite its name, is a global REIT that owns and operates communications towers. The company generally leases its land, builds a tower on it, and rents space on the top of the tower to mobile carriers, radio and television providers, and other tenants.

  • [By Chris Neiger]

    That’s why it’s important to think about adding some dividend stocks to your retirement portfolio so that you can not only receive some additional income but also build wealth at the same time. To help you get started, let’s take a look at why three very different companies — 3M (NYSE:MMM), Apple (NASDAQ:AAPL), American Tower (NYSE:AMT) — could be great long-term investments for your retirement.

Top 5 High Tech Stocks To Buy Right Now: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By ]

    Edwards Lifesciences (EW) : “They have the best devices. That stock is a buy.”

    Align Technology (ALGN) : “The stock is breaking down. Let’s wait a few days then pull the trigger.”

  • [By ]

    In the Lightning Round, Cramer was bullish on Align Technology (ALGN) , Regions Financial (RF) , Edwards Lifesciences (EW) , Qualys (QLYS) and HEICO (HEI) .

  • [By Logan Wallace]

    Sanford C. Bernstein began coverage on shares of Edwards Lifesciences (NYSE:EW). Sanford C. Bernstein issued a market perform rating on the stock.

Top 10 Warren Buffett Stocks To Watch Right Now

The Kraft Heinz Co. is a $100 billion market capitalization company that generates more than $26 billion in annual revenue by selling iconic brands like Heinz Ketchup, Velveeta Cheese and Kraft Macaroni. Starting in October, Kraft Heinzs finances will be overseen by a 29-year-old.

The company announced on Friday that David Knopf will be the new chief financial officer of Kraft Heinz. Knopf has been working since 2015 at Kraft Heinz, where his responsibilities included overseeing the Planters Nuts brand and heading global budget and business planning, as well as zero-based budgeting and financial strategic planning as a vice-president.

LinkedIn

David Knopf’s LinkedIn page.

Knopf is also a partner at 3G Capital, the private equity firm backed by billionaires Jorge Paulo Lemann, Carlos Alberto Sicupira, and Marcel Herrmann Telles. 3G partnered with Warren Buffett to buy Heinz in a $23 billion deal and then merged the company with Kraft.

Top 10 Warren Buffett Stocks To Watch Right Now: Westell Technologies, Inc.(WSTL)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested small cap high-performance wireless infrastructure solutions stock Westell Technologies (NASDAQ: WSTL) as a buy for our short-term portfolio:

Top 10 Warren Buffett Stocks To Watch Right Now: The Herzfeld Caribbean Basin Fund, Inc.(CUBA)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    This "Trump pick" is a snub to the President’s trade and diplomatic reversals of Obama’s wins regarding Cuba. We are buying back Herzfeld Caribbean Basin Fund (CUBA), following in the footsteps of its founder, Tom Herzfeld, and his son Erik.

Top 10 Warren Buffett Stocks To Watch Right Now: Statoil ASA(STO)

Advisors’ Opinion:

  • [By Cameron Swinehart]

    Going forward I will be looking to add investments on my watchlist and trim other positions. It will be interesting to see how an overweight commodity portfolio will perform relative to the rest of the market.

     Cost Basis# SharesCurrent Price% of PortfolioCurrent ValueReturnMetal/Miners      Sprott Physical Gold Trust (PHYS)$12.4985$11.043.75%$938.40-13.13%Sprott Physical Silver Trust (PSLV)$7.95125$8.744.37%$1,092.509.04%FreePort-McMoran (FCX)$31.6731$33.874.20%$1,049.976.50%Ishares MSCI Global Gold Miners ETF (RING)$13.0695$10.644.04%$1,010.80-22.74%Energy      Statoil ASA(STO)$21.7940$22.683.63%$907.203.92%Vanguard Natural Resources LLC (VNR)$27.5636$27.874.01%$1,003.321.11%ConocoPhillips (COP)$63.6822.43$71.006.37%$1,592.5310.31%Agriculture      CVR Partner LP (UAN)$26.3630.9$18.932.34%$584.94-39.25%Adecoagro$6.78125$7.443.72%$930.008.87%Archer-Daniels Midland (ADM)$34.8030$37.244.47%$1,117.206.55%Mixed Commodity      Powershares DB Commodity Index (DBC)$26.3540$25.954.15%$1,038.00-1.54%Sprott Resource Corp$3.34400$2.714.34%$1,084.00-23.25%    Total % of portfolio49.40%               Cost Basis12,666.00      Current Value12,348.86      Return-2.50%  Source: Investing For The Future Surge In Commodity Prices

    Disclosure: I am long ADM, FCX, UAN, AGRO, RING, VNR, SCPZF.PK, COP, DBC, PHYS, PSLV. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More…)

  • [By Jayson Derrick]

    BP plc (ADR) (NYSE: BP), Royal Dutch Shell plc (ADR) (NYSE: RDS-A) (NYSE: RDS-B) and Statoil ASA(ADR) (NYSE: STO) are expected to outperform their peers by offering: 1) the greatest rate of change in cost reduction through technology and innovation, 2) upstream portfolios with an attractive risk to reward profile and 3) sufficient liquidity to invest in future growth.

  • [By Ben Levisohn]

    We believe that the equity market has neutralised much of its underweight energy positioning in 4Q/1Q, but was caught by the sharp rally in crude from end-January. Our base-case sees oil prices still higher by end-2016 (we see >$50/bbl), albeit with a choppy 2Q likely ahead. In this scenario a modest, rather than fully-fledged price-recovery we continue to place a lot of importance on self-help in driving ROE expansion (as opposed to relying simply on oil-leverage). Value-adjusted, we like the self-help stories around Total, Chevron, Statoil (STO), Royal Dutch Shell and Eni (E) in the group. Total is on the Citi European Focus list.

  • [By Paul Ausick]

    Norway’s Statoil ASA (NYSE: STO) announced this morning that it has acquired stakes in two North Sea projects from France’s Total S.A. (NYSE: TOT). The transaction, valued at $1.45 billion, includes a 51% equity stake in the Martin Linge field and a 40% stake in the Garantiana discovery, both located on Norway’s continental shelf.

  • [By Todd Shriber, ETF Professor]

    NORW reflects Norway's oil exposure. The ETF allocates nearly 28.8 percent of its weight to the energy, 870 basis points more than it devotes to its second-largest sector exposure, financial services. State-run Statoil ASA(ADR) (NYSE: STO) is NORW's largest individual holding at a weight of 15.3 percent, or 560 basis points more than NORW allocates to its second-largest holding.

  • [By Ben Levisohn]

    Should oil prices recover, we believe that deepwater drilling activity growth should lag growth in US shale activity, as project economics is generally better in US shales, and E&Ps involved in US shales are generally quicker to react. Deepwater activity is largely comprises a handful of companies (Petrobras (PBR), Statoil (STO), Total (TOT), Shell (RDS.A), BP (BP), ONGC, ExxonMobil (XOM) and Chevron (CVX)) and it is unlikely that these companies can meaningfully increase their rig demand in a short period of time to absorb the current oversupply. Thus, should oil prices rise in 2018, rig demand may increase, but likely not enough to tighten the market, given that supply equaling 43% of current working rig count is stacked and new supply equaling 25% of working rig count is under-construction and should be entering the market in the coming years. As a result, while we expect some improvement in rig utilization owing to rig retirements, it will unlikely be strong enough to meaningfully improve rates in 2018 above spot levels. Any demand increase in the interim could slow rig retirements materially, and be self-defeating. We thus are Sell rated on Transocean, Atwood and Noble.

Top 10 Warren Buffett Stocks To Watch Right Now: SandRidge Mississippian Trust II(SDR)

Advisors’ Opinion:

  • [By Paul Ausick]

    Sandridge Mississippian Trust II (NYSE: SDR) dropped about 18% Monday to post a new 52-week low of $0.75 after closing at $0.95 on Friday. The 52-week high is $1.79. Volume was around 1.3 million, more than nine times the daily average of around 160,000. The company had no specific news.

Top 10 Warren Buffett Stocks To Watch Right Now: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Top 10 Warren Buffett Stocks To Watch Right Now: Vince Holding Corp.(VNCE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Vince Holding Corp (NYSE: VNCE) were down around 15 percent to $3.67. Vince Holding projects full-year sales and EPS to come in at or below the low end of its earlier issued outlook.

  • [By Peter Graham]

    Small cap upscale apparel brandretailer Vince Holding Corp (NYSE: VNCE) reported Q1 2017 financial results before the market opened this morning. Net sales decreased 14.2% to $58.0 million as wholesale segment sales decreased 20.9% to $35.4 million, primarily due to a reduction in full-price orders as a result of the elimination of the Companys summer delivery, and asdirect-to-consumer segment salesfell 1.0% to $22.6 million. Comparable sales decreased 5.7%, including e-commerce sales, due to a decrease in average order value.

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Lisa Levin]

    Shares of Vince Holding Corp (NYSE: VNCE) were down around 41 percent to $0.800. Vince Holding reported a Q4 loss of $162.1 million on revenue of $63.9 million.

Top 10 Warren Buffett Stocks To Watch Right Now: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

Top 10 Warren Buffett Stocks To Watch Right Now: Zumiez Inc.(ZUMZ)

Advisors’ Opinion:

  • [By Chris Lange]

    Zumiez Inc. (NASDAQ: ZUMZ) is set to report its fiscal second-quarter results on Thursday. The consensus estimates predicta net loss of $0.08 per share and $177.35 million in revenue. Shares were changing hands at $16.61 on Fridays close. The consensus price target is $15.20, and the stock has a 52-week range of $11.53 to $23.45.

  • [By Lisa Levin]

    Zumiez Inc. (NASDAQ: ZUMZ) was down, falling around 10 percent to $19.78. Zumiez reported in-line earnings for its third quarter on Thursday.

    Commodities

  • [By Lisa Levin]

    Zumiez Inc. (NASDAQ: ZUMZ) was down, falling around 12 percent to $19.15. Zumiez reported in-line earnings for its third quarter on Thursday.

    Commodities

  • [By Dan Caplinger]

    Friday was a good day on Wall Street, as the stock market responded favorably to encouraging news on the employment front. The U.S. unemployment rate dropped on fairly strong job creation during the month of February, and that helped push the Dow, S&P 500, and Nasdaq Composite to modest gains of roughly between a quarter percent and a half percent. Yet even with a positive mood among market participants, some stocks weren’t able to participate in the end-of-week rally. Finisar (NASDAQ:FNSR), Zumiez (NASDAQ:ZUMZ), and Winnebago Industries (NYSE:WGO) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top 10 Warren Buffett Stocks To Watch Right Now: Arch Coal, Inc. (ARCH)

Advisors’ Opinion:

  • [By Ben Levisohn]

    The VanEck Vectors Coal ETF has gained 1.1% to $12.28 at 2:01 p.m. today, while Arch Coal (ARCH), which resumed listed trading yesterday after emerging from bankruptcy, has fallen 3% to $62.98.

Top 10 Warren Buffett Stocks To Watch Right Now: Daktronics, Inc.(DAKT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is projected to report its quarterly earnings at $0.08 per share on revenue of $156.17 million.

    Guidewire Software Inc (NYSE: GWRE) is estimated to post its quarterly earnings at $0.06 per share on revenue of $92.43 million.

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is estimated to report its quarterly earnings at $0.08 per share on revenue of $156.17 million. Daktronics shares slipped 0.13 percent to close at $7.97 on Tuesday.

Best Safest Stocks To Own For 2018

Gasoline futures soared Monday as Tropical Storm Harvey continued to wreak havoc on Texas, knocking major Gulf Coast refineries out of action.

And while the storm is also expected to curtail offshore crude oil production in the Gulf of Mexico, crude futures are under pressure. Thats because the supply impact is more than offset by the hit to demand for crude by the refinery shutdowns.

See: Hurricane Harvey highlights biggest impact of shale-oil revolution

Best Safest Stocks To Own For 2018: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

Best Safest Stocks To Own For 2018: Tucows Inc.(TCX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tucows Inc. (USA) (NASDAQ: TCX) shares shot up 17 percent to $42.45 after the company announced plans to acquire eNom from Rightside for $83.5 million.

  • [By Anders Bylund]

    Shares of Tucows (NASDAQ:TCX) rose 12.1% in March 2017, according to data from S&P Global Market Intelligence.

    So what

    The provider of online business services and a budding bundle of mobile and fiber-optic communications products started March with a bang, announcing a brand-new $40 million share buyback program. For a company with a $476 million market cap at the time, that’s a pretty serious and shareholder-friendly commitment.

Best Safest Stocks To Own For 2018: Black Diamond, Inc.(BDE)

Advisors’ Opinion:

  • [By Jim Robertson]

    At the beginning of the week, our Under the Radar Moversnewsletter suggested small cap sporting & outdoor goods stock Black Diamond Inc (NASDAQ: BDE) as a short/bearish trade:

Best Safest Stocks To Own For 2018: Unilever NV(UN)

Advisors’ Opinion:

  • [By Teresa Rivas]

    Earlier this year, Unilever (UN) recently declined Kraft Heinz (KHC) merger bid. That means that if the company still wants to do a deal, Mondelez International (MDLZ) and PepsiCo (PEP) are the next logical partners, writes Susquehannas Pablo Zuanic.

    Getty Images

    Zuanic upgraded Pepsi from Neutral to Positive today and raised his price target from $118 to $132. He writes that a Pepsi deal would have more strategic merits, hence his upgrade (as he emphasizes that not much has changed in terms of fundamentals for the firm).

    More detail from his note:

    With investors apparently seeing MDLZ as the next likely KHC target, and Coca-Cola (KO) the next Anheuser-Busch (BUD) target, PEP shares have lost visibility and now trade at a 25% discount to KO on apples-to-apples comps. We see value here, on franchise strength, efforts to align the F&B portfolio with consumer health trends, and the growing optionality value of a joint KHC/BUD bid for PEP. We argue that, together, the Kendall Jenner commercial, the Aspartame to-be-or-not-to-be zigzagging, the new, new, new alt low-cal cola (Pepsi Zero sugar), the ongoing underperformance in U.S. CSDs (25% only of the company), the lack of scale in non-CSD NARTDs vs. KO (other than Gatorade), and now talk of PEP buying Brazilian dairy company Vigor S.A. (a JBS subsidiary that would better fit KHC or ULVR), all paint a picture of a company still struggling to set a new direction (with all due respect). In this regard, we think PEP may be more vulnerable than MDLZ to a KHC bid (jointly done with BUD). We also see greater strategic fit for KHC with PEP Food/Snacks (than with MDLZ), and argue that PEP Beverages fits BUD better than KO, as the PEP bottling operations in key regions (including NA) remain in the hands of PEP (KO, on the other hand will be fully refranchised by end of 2017). So we are upgrading PEP to Positive with a $132 price target by December 17. Yes, the Unilever rebuff

  • [By Lisa Levin]

    In trading on Tuesday, industrial shares fell by 0.04 percent. Meanwhile, top losers in the sector included Unilever N.V. (ADR) (NYSE: UN), down 8 percent, and Magal Security Systems Ltd. (USA) (NASDAQ: MAGS), down 6 percent.

Top 10 Medical Stocks To Buy For 2018

We’re one day from the election, and there are a number of marijuana initiatives on state ballots.

That’s why we’re featuring the top marijuana stocks to watch now. You see, this week is poised to be the biggest week of the year for marijuana stocks. In fact, this week could be historic for the legal and medical marijuana industry.

A record nine states have marijuana initiatives on the ballot this year.

Legal use of recreational marijuana is on the ballot in Arizona, California, Maine, Massachusetts, and Nevada. If passed, those five states will join Alaska, Colorado, Oregon, Washington, and the District of Columba, where adults are free to use marijuana recreationally.

Medical marijuana initiatives are on the ballot in Arkansas, Florida, Montana, and North Dakota.

Top 10 Medical Stocks To Buy For 2018: Panasonic Corporation (PCRFY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    A Unilever vs. Panasonic (OTCPK:PCRFY) showdown seems to be something out of an alternative, weird universe. But that’s exactly what has been happening in the Asia-Pacific region, where Unilever is now a major seller of air and water purification devices. The acquisitions of Qinyuan and Pureit water purifiers, as well as the acquisition of Sweden-based Blueair in 2016, reflects Unilever’s latest growth strategy of reducing exposure to low-growth brands in favor of greater investments in higher-growth products with strong social and environmental credentials.

  • [By SEEKINGALPHA.COM]

    SMMYY is a subsidiary of the Sumitomo Group. SMMYY is a major smelter and refiner of copper, nickel and gold in Japan, and has a 27.5% stake in the Ambatovy Nickel Project in Madagascar, along with Sherritt International and Korea Resources Corp. Feedstock for the refinery is nickel cobalt mixed sulphide from its Taganito and Coral Bay mines in the Philippines (noting the Philippines is a risky supply source at this time). Sumitomo supply Panasonic (OTCPK:PCRFY) who supply Tesla (NASDAQ:TSLA); however, this can change. Generally, I like the stock; however, at this time, valuation looks full, trading on a 2017 PE of 32.8, and 2018 PE of 14.8. Good to buy after a pullback if that occurs.

  • [By SEEKINGALPHA.COM]

    Clean Technica reported on September 1 that “Sony is entering the EV battery manufacturing industry”. And “considering that electric vehicle batteries are going to be the main supply bottleneck for the upcoming auto market’s embrace of EVs, the entry of Sony into the field is very notable. Most of the other manufacturers (Panasonic (OTCPK:PCRFY), LG Chem (OTC:LGCLF), etc.) already have more or less all of their production capacity locked up for the coming years – meaning there’s not much left for the auto manufacturers that are running behind, thereby limiting potential EV sales for the firms in question. Sony’s (NYSE:SNE) entry into the field should open things up a bit more”. Certainly a good move by Sony and helpful for the EV companies that will find themselves in need of batteries, and limited availability, should EVs reach 10% by 2020.

  • [By Ben Levisohn]

    During the early stages of a new innovation, interdependent architectures and integrated companies best optimize performance and functionality. This trend has played out in computing and handsets, and we see the same trend playing out in EVs. We find Tesla and BYD1 , by far, the most vertically integrated players in EVs, with huge scale advantages. In addition, LG Chem, Panasonic (PCRFY), Samsung SDI, BYD, and CATL are clear scale leaders in batteries (CATL is not publicly traded. All but Samsung SDI and BYD are not covered by Bernstein.).

Top 10 Medical Stocks To Buy For 2018: Semtech Corporation(SMTC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Semtech Corporation (NASDAQ: SMTC) is projected to post its quarterly earnings at $0.27 per share on revenue of $128.38 million.

    Ollie’s Bargain Outlet Holdings Inc (NASDAQ: OLLI) is estimated to post its quarterly earnings at $0.17 per share on revenue of $190.44 million.

Top 10 Medical Stocks To Buy For 2018: Hostess Brands, Inc. (TWNK)

Advisors’ Opinion:

  • [By Paul Ausick]

    There was an IPO of sorts last week when Gores Holdings II raised $375 million with an offer of 37.5 million units at $10 per unit. The shares are listed on the Nasdaq under the ticker symbol GSHTU. Gores Holdings I acquired Hostess Brands last year and completed an IPO in December for Hostess Brands Inc. (NASDAQ: TWNK).

Top 10 Medical Stocks To Buy For 2018: Staffing 360 Solutions, Inc.(STAF)

Advisors’ Opinion:

  • [By Bryan Murphy]

    The staffing industry – and the IT staffing industry in particular – is poised for tremendous growth in the foreseeable future, and that rising tide bodes very well for Staffing 360 Solutions Inc. (NASDAQ:STAF).

  • [By Matthew Briar]

    If there was any lingering doubt about Staffing 360 Solutions Inc (NASDAQ:STAF), it was wiped away today. The IT staffing firm’s second quarter numbers verify the long-standing growth trend is still well intact. Better still, even as the top line rises, expense-cuts supported by all the synergies of its recent acquisitions have allowed the bottom line to improve by even more.

    Even before today’s official Q2 announcement we knew that last quarter’s revenue would roll in at $47.1 million and gross profits would end up at $8.1 million. Those figures were up 14% and 8.4%, respectively. What we didn’t know about STAF until today is that the net loss shrank from $3.4 million a year earlier to only $1.5 million now. EBITDA of $1.4 million was about the same as the EBITDA of $1.3 million generated in the second fiscal quarter of the prior year.

    The progress march continues for Staffing 360 Solutions.

  • [By James E. Brumley]

    It’s almost time for the annual Staffing 360 Solutions Inc (NASDAQ:STAF) shareholder pow-wow. That is to say, the company’s annual shareholder meeting is scheduled for January 26th of the coming year, in New York City. Though nothing too dramatic is on the voting docket, a handful of items will be decided on by STAF owners.

    Staffing 360 Solutions is a fast-growing staffing firm. Its focal point is IT staffing. This small company is smartly and cost-effectively acquiring its way into a size and scale by converting a fragmented and less-effective and less profitable group of similar staffing agencies into a cohesive, more profitable singular unit.

    It’s paying off too – the proof has been in the rising revenue tally over the course of the past couple of years… a rise that’s been outpaced by the broad improvement of EBITDA and income (which is the point of a scale-up).

    The specific numbers: . All told, Staffing 360 Solutions generated $47.8 million worth of revenue last quarter, turned $8.5 million of it into a gross profit, and turned $1.8 million of that into an EBITDA profit. Those were, respectively, improvements of 33%, 34%, and 184% compared to the same quarter a year earlier. Net income improved too. The net loss of $1.3 million was 27% smaller than the net loss of $1.7 million booked in Q1 of fiscal 2016. Profitability – real profitability – is within reach. STAF simply has to stay on the trajectory it’s on. A couple more acquisitions and a little more organic growth could do the trick.

    Late next month, shareholders will have a chance to voice their thoughts on where the company should be going… metaphorically and literally. One of the matter being put to a vote is a change of domicile, from Nevada to Delaware; Delaware generally offers a more business-friendly set of operating and tax rules. Another more important matter to be voted on at the meeting is the authorization of more STAF shares, which have been used in lie

  • [By Peter Graham]

    Small cap staffing stock Staffing 360 Solutions Inc (NASDAQ: STAF), which is in the midst of a global buy-and-build strategy through the acquisition of domestic and international staffing organizations with operations in the US and UK, pre-announced its unaudited financial results for the fiscal second quarter ended November 30, 2016. Expected revenue rose 14% to$47 million and expected gross profit rose 8% to $8.1 million while for the first six months of the fiscal year, expected revenuerose 23% to$95 million and expected gross profit rose 20% to $16.6 million.

  • [By Matthew Briar]

    Staffing 360 Solutions Inc (NASDAQ:STAF) is on a roll. Just a couple of days after it pre-announced some impressive preliminary results for the most recently-completed quarter, the IT staffing agency told STAF shareholders today that $2.7 million worth of debt had essentially been refinanced. Now, no interest payments are due until October of this year, and no principal is due until October of next year. That may well be enough time for Staffing 360 Solutions to acquire more companies, beef up the top and bottom line, and pay the whole amount off before another refinancing or conversion to shares.

    Staffing 360 Solutions’ story is a compelling one. Seeing the growing need for information technology workers in an increasingly digital and increasingly networked world — and a severe lack of those qualified workers — three years ago the company began to capitalize on the supply/demand imbalance. Its mission was to aggregate, or “roll up” several smaller IT staffing companies into one big one, create some synergies and thus widen margins, and develop enough muscle to become THE dominant name in the niche.

    It’s working too. On Tuesday of this week, the company pre-announced its fiscal first quarter (ending in November) sales and gross profits. Revenue of $47 million and a gross profit of $8.1 million were up 14% and 8%, respectively, year-over-year, extending a long-term growth trend.

    What we haven’t heard yet — and won’t until the official Q1 filing is submitted later this month — is the company’s net income and EBITDA figures for the quarter. But, those numbers are improving too. EBITDA has been positive in each of the five prior quarters, and is expected to continue growing through last quarter. Net income is within sight of turning positive too. And, with its debt-interest payments now going away for at least nine months, net income will move towards turning positive at an even faster rate… through lower expenses, as well as greater fin

Top 10 Medical Stocks To Buy For 2018: U.S. Physical Therapy, Inc.(USPH)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares fell 0.73 percent. Meanwhile, top losers in the sector included U.S. Physical Therapy, Inc. (NYSE: USPH), down 7 percent, and Fluidigm Corporation (NASDAQ: FLDM), down 7 percent.

Top 10 Medical Stocks To Buy For 2018: Realogy Holdings Corp.(RLGY)

Advisors’ Opinion:

  • [By Chad Tracy]

    Investments in Claire's retail stores, Realogy Holdings (NYSE: RLGY), and Harrah's Entertainment all came under pressure as the global credit crisis hit. Apollo was forced to shut off cash interest payments to investors and to issue more debt.  

  • [By Lisa Abramowicz]

    Drugstore chain Rite Aid Corp. (RAD) and residential property firm Realogy Corp. (RLGY) are two of the 283 junk-rated borrowers identified in March 2009 by Moodys Investors Service as being at the highest risk of default that have since sold bonds.

  • [By Monica Wolfe]

    Realogy Holdings (RLGY)

    Paulsons third largest holding goes to Realogy Holdings. The guru holds on to 12,957,700 shares, representing 4.4% of his total portfolio and 8.87% of the companys shares outstanding.

Top 10 Medical Stocks To Buy For 2018: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

Top 10 Medical Stocks To Buy For 2018: Teck Resources Ltd(TCK)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Stephens (Equal-Weight) and Citi (Sell) both downgraded Atwood Oceanics (NYSE: ATW).

    Sell-Side's Most Noteworthy Calls
    Investec downgraded Anheuser-Busch (NYSE: BUD) to Hold.
    Deutsche Bank downgraded Freeport McMoRan (NYSE: FCX) to Hold.
    Goldman Sachs upgraded Microsoft (NASDAQ: MSFT) to Buy.
    Barclays upgraded Teck Resources (NYSE: TCK) to Overweight.
    BTIG started Adobe (NASDAQ: ADBE) at Neutral.
    Deal Talk

    U.S. oil refiner Tesoro (NYSE: TSO) said it would buy Western Refining (NYSE: WNR) for $4.1 billion to add refineries in Texas, New Mexico and Minnesota. The combined company will have refining capacity of over 1.1 million barrels per day. Tesoro has refineries in California, Washington, Alaska, Utah and North Dakota.

Top 10 Medical Stocks To Buy For 2018: iShares MSCI Emerging Markets (EEM)

Advisors’ Opinion:

  • [By Dan Caplinger]

    2017 has been a tumultuous year, with plenty going on in the political and financial realms. Yet the stock market has done quite well, and index funds that track popular stock benchmarks have given their investors solid returns. In particular, among the most popular exchange-traded funds, iShares MSCI Emerging Markets (NYSEMKT:EEM), PowerShares QQQ (NASDAQ:QQQ), and iShares Core MSCI EAFE (NYSEMKT:IEFA) have delivered some of the best returns.

  • [By WWW.GURUFOCUS.COM]

    For the details of RABOBANK NEDERLAND ‘s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=RABOBANK+NEDERLAND+

    These are the top 5 holdings of RABOBANK NEDERLAND Bank of America Corporation (BAC) – 250,000 shares, 100% of the total portfolio. New PositionBlackBerry Ltd (BBRY) – 0 shares, 0% of the total portfolio. Shares reduced by 10000%iShares MSCI Emerging Index Fund (EEM) – 0 shares, 0% of the total portfolio. Shares reduced by 10000%iShares MSCI Brazil Capped Index Fund (EWZ) – 0 shares, 0% of the total portfolio. Shares reduced by 10000%VanEck Vectors Gold Miners (GDX) – 0 shares, 0% of the total portfolio. Shares reduced by 10000%

  • [By Craig Jones]

    On CNBC's Trading Nation, Todd Gordon recommended a bearish options strategy in iShares MSCI Emerging Markets Indx (ETF) (NYSE: EEM). He said that the ETF is under pressure because of weak commodity prices and strong U.S. dollar. He explained that falling bond prices have caused a rally in the U.S. dollar.

  • [By Craig Jones]

    Speaking on Bloomberg Markets, Dan Deming of KKM Financial suggested a bullish options strategy in iShares MSCI Emerging Markets Indx (ETF) (NYSE: EEM).

Top 10 Medical Stocks To Buy For 2018: Nordstrom Inc.(JWN)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    There seems to be no cure for the rise of e-commerce, Cramer admitted to viewers, as a vicious downgrade of Nordstrom (JWN) last week sent shares reeling by more than 9%.

  • [By Chris Lange]

    Nordstrom, Inc. (NYSE: JWN) reported fiscal first-quarter financial results after markets closed Thursday. The company reported $0.43 in earnings per share (EPS) and $3.3 billion in revenue versus consensus estimates from Thomson Reuters that called for $0.27 in EPS and $3.34 billion in revenue. The same period from last year had $0.26 in EPS and $3.25 billion in revenue.

  • [By Dan Caplinger]

    The retail industry has gone through tough times lately, and things have been especially difficult for high-end retailers like Nordstrom (NYSE:JWN). As shoppers become more comfortable with online shopping, department stores with substantial brick-and-mortar assets have had to adapt to changes in consumer behavior and meet them on their own terms, and that’s been a difficult proposition for a company that prides itself on one-on-one customer service in the store setting.